In an editorial published in the New England Journal of Medicine, University of Michigan Health hepatologist Anna S. Lok, M.D ...
The sneaky virus poses serious health threats if it goes on to become a chronic disease. Clinical trial results suggest a new drug may cure 1 in 5 of those cases.
Schematic representation of histone-modifying factor recruitment on cccDNA minichromosomes in relation to viral protein HBx. In the presence of HBx, histone-modifying factors such as p300/CBP, Set1A, ...
Two replicate phase 3 randomized controlled trials involving patients with chronic hepatitis B virus (HBV) infection demonstrate a functional cure after the discontinuation of conventional long-term ...
After treatment with bepirovirsen, however, 19% of patients achieved the strictly defined “functional cure” criteria. For the ...
The antisense oligonucleotide was even more effective in patients with relatively low viral activity. More than one-quarter of these individuals had undetectable levels of the virus in the blood for ...
New research implies that a first-of-its-kind drug for hepatitis B could allow some patients to stop treatment without showing signs of the dangerous virus.
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
Tune-401 achieved dose-dependent HBsAg reductions (mean 54% at 0.65 mg/kg) with durable, months-long pharmacodynamics after single dosing on stable nucleos(t)ide analog background. Multiple recipients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results